Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study
Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 96 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Gobierno
- National Center for Advancing Translational Sciences
- Gobierno
- NIAMS NIH HHS
- Gobierno
- NCATS NIH HHS
- Subvenciones
- National Center for Advancing Translational Sciences (UL1 TR000454); National Institute of Arthritis and Musculoskeletal and Skin Diseases (K23 AR054334)
Según 4 financiadores declarados.
Publicación
- Publicado
- 2008-01-01 · Endocr Pract · vol. 14 · número 1 · págs. 10–17
- Editorial
- Elsevier BV
- Citado
- 142 citas · más que el 98% de estudios similares · 10.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 62 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Parathyroid Disorders and Treatments · Vitamin D Research Studies · Dialysis and Renal Disease Management
- Palabras clave
- vitamin D3, vitamin D3 supplementation, vitamin D insufficiency, chronic kidney disease, 25-hydroxyvitamin D, parathyroid hormone, secondary hyperparathyroidism, 1,25-dihydroxyvitamin D, bone turnover markers
- MeSH
- humans, vitamin d deficiency, calcium, cholecalciferol, collagen type i, parathyroid hormone, acid phosphatase, alkaline phosphatase, isoenzymes, vitamin d, peptides, placebos, pilot projects, double-blind method, adolescent, adult, aged, aged, 80 and over, middle aged, renal insufficiency, chronic, tartrate-resistant acid phosphatase
7 autores
- Prakash Chandra🇺🇸Emory University
- José Binongo
- Thomas R. Ziegler🇺🇸Emory University
- Lynn E. Schlanger🇺🇸Emory University
- Wenli Wang🇺🇸Emory University
- James T. Someren🇺🇸Emory University
- Vin Tangpricha🇺🇸 · autor de correspondenciaEmory University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
To investigate the efficacy of cholecalciferol (vitamin D3) in raising serum 25-hydroxyvitamin D (25[OH)]D) levels and reducing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD).
Methods
In this double-blind, randomized controlled pilot study, participants with CKD stage 3 and 4 (estimated glomerular filtration rate, 15-59 mL/min/1.73 m2), vitamin D insufficiency (serum 25[OH]D 70 pg/mL were randomly assigned to receive either 50 000 IU of cholecalciferol or placebo once weekly for 12 weeks. Primary outcomes (25[OH]D and PTH levels) were measured at baseline, week 6, and week 12. Secondary outcomes (1,25-dihydroxvitamin D and bone turnover markers) were measured at baseline and week 12. Because of skewed data distribution, statistical analyses were performed on a logarithmic scale. The difference between the group means was exponentiated to provide the geometric mean ratio. A linear mixed model using an unstructured variance-covariance matrix was used to examine change in the primary and secondary outcomes over time.
Results
Geometric mean serum 25(OH)D concentrations of the study groups were similar at baseline (P = .77). At week 6, a significant difference between the treatment and placebo groups was detected (P = .001); this difference was maintained at week 12 (P = .002). Among cholecalciferol-treated participants, serum 25(OH)D concentration increased on average from 17.3 ng/mL (95% confidence interval [CI], 11.8-25.2) at baseline to 49.4 ng/mL (95% CI, 33.9-72.0) at week 12. As-treated analysis indicated a trend toward lower PTH levels among cholecalciferol-treated participants (P = .07).
Conclusion
Weekly cholecalciferol supplementation appears to be an effective treatment to correct vitamin D status in patients with CKD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.